Omeros Corporation (OMER) Given “Buy” Rating at WBB Securities
Omeros Corporation (NASDAQ:OMER)‘s stock had its “buy” rating reissued by research analysts at WBB Securities in a research note issued on Monday. They presently have a $75.00 price target on the biopharmaceutical company’s stock.
A number of other analysts also recently issued reports on OMER. FBR & Co reissued an “outperform” rating and issued a $38.00 target price on shares of Omeros Corporation in a research report on Wednesday, June 29th. Zacks Investment Research downgraded Omeros Corporation from a “hold” rating to a “sell” rating in a research report on Wednesday, July 13th. Maxim Group reissued a “buy” rating and issued a $30.00 target price on shares of Omeros Corporation in a research report on Thursday, July 28th. Cantor Fitzgerald reissued a “buy” rating and issued a $21.00 target price on shares of Omeros Corporation in a research report on Wednesday, August 10th. Finally, Wedbush reaffirmed an “outperform” rating and issued a $56.00 price target (down from $62.00) on shares of Omeros Corporation in a report on Thursday, August 11th. One research analyst has rated the stock with a sell rating and six have given a buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus target price of $32.45.
Omeros Corporation (NASDAQ:OMER) traded up 3.54% during trading on Monday, hitting $7.60. The stock had a trading volume of 3,868,671 shares. The stock’s market capitalization is $298.63 million. Omeros Corporation has a 52 week low of $7.26 and a 52 week high of $16.80. The company has a 50-day moving average of $10.60 and a 200-day moving average of $11.73.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at https://www.americanbankingnews.com/2016/10/17/omeros-corporation-omer-given-buy-rating-at-wbb-securities.html
Omeros Corporation (NASDAQ:OMER) last released its earnings results on Tuesday, August 9th. The biopharmaceutical company reported ($0.32) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.50) by $0.18. The firm earned $10 million during the quarter, compared to analysts’ expectations of $9.80 million. During the same period in the prior year, the business earned ($0.44) earnings per share. The business’s quarterly revenue was up 212.5% compared to the same quarter last year. On average, equities analysts expect that Omeros Corporation will post ($1.55) earnings per share for the current fiscal year.
In related news, VP Marcia S. Kelbon sold 16,000 shares of Omeros Corporation stock in a transaction on Thursday, September 15th. The stock was sold at an average price of $10.91, for a total transaction of $174,560.00. Following the completion of the sale, the vice president now owns 179,597 shares of the company’s stock, valued at $1,959,403.27. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, VP Marcia S. Kelbon sold 15,900 shares of Omeros Corporation stock in a transaction on Monday, August 15th. The shares were sold at an average price of $11.56, for a total value of $183,804.00. Following the sale, the vice president now directly owns 179,497 shares of the company’s stock, valued at approximately $2,074,985.32. The disclosure for this sale can be found here. Corporate insiders own 13.60% of the company’s stock.
Large investors have recently bought and sold shares of the stock. Nationwide Fund Advisors raised its stake in Omeros Corporation by 183.9% in the fourth quarter. Nationwide Fund Advisors now owns 69,700 shares of the biopharmaceutical company’s stock valued at $1,096,000 after buying an additional 45,145 shares in the last quarter. California State Teachers Retirement System raised its stake in shares of Omeros Corporation by 1.8% in the fourth quarter. California State Teachers Retirement System now owns 70,144 shares of the biopharmaceutical company’s stock valued at $1,103,000 after buying an additional 1,249 shares during the period. Tocqueville Asset Management L.P. raised its stake in shares of Omeros Corporation by 4.9% in the fourth quarter. Tocqueville Asset Management L.P. now owns 1,533,581 shares of the biopharmaceutical company’s stock valued at $24,123,000 after buying an additional 71,954 shares during the period. Stoneridge Investment Partners LLC raised its stake in shares of Omeros Corporation by 3.6% in the fourth quarter. Stoneridge Investment Partners LLC now owns 320,463 shares of the biopharmaceutical company’s stock valued at $5,041,000 after buying an additional 11,184 shares during the period. Finally, Brown Advisory Inc. raised its stake in shares of Omeros Corporation by 44.6% in the fourth quarter. Brown Advisory Inc. now owns 529,699 shares of the biopharmaceutical company’s stock valued at $8,332,000 after buying an additional 163,306 shares during the period. 48.04% of the stock is owned by institutional investors.
Omeros Corporation Company Profile
Omeros Corporation is a biopharmaceutical company engaged in discovering, developing and commercializing small-molecule and protein therapeutics for market, as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system. The Company’s marketed drug product, Omidria (phenylephrine and ketorolac injection), is used during cataract surgery or intraocular lens replacement.
Receive News & Ratings for Omeros Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omeros Corporation and related companies with MarketBeat.com's FREE daily email newsletter.